HAMILTON, N.J., June 21, 2016 /PRNewswire/ -- MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, announced two new members of its Board of Directors: Richard F. Cimino, former Covance, Inc. EVP and Group President of Clinical Development and Commercialization Services, and Nigel Brown, former Corporate Vice President of Business Development and Strategy at Covance.
Mr. Cimino and Dr. Brown join MedAvante at a critical time as the company continues to expand both its global presence and the range of therapeutic areas in which its Virgil® Investigative Study Platform powers clinical trials. As former Covance leadership team executives and Contract Research Organization (CRO) veterans, their experience, clinical knowledge and strategic acumen will be critical as MedAvante consolidates its position as the leader in electronic source data (eSource).
"As the experienced pioneer in eSource data, MedAvante is on the leading edge of a clear transition in pharmaceutical clinical trials – the shift from paper-based trials to digital," said MedAvante CEO Paul Gilbert. "Rick and Nigel both possess the experience as well as the strategic vision to recognize the enormous advantages drug developers gain through smarter, faster clinical trials. They will make significant and substantive contributions to MedAvante's growth as we reduce the time and cost companies require to get vital drugs to the patients who need them."
Mr. Cimino brings a wealth of experience in global clinical pharmacology, early clinical development, and Phase II-IV clinical development as well as in business development and strategic marketing. He served 11 years on the Covance Executive Committee, through 2015. Prior to this, Mr. Cimino worked for 20 years at Eastman Kodak, where he was instrumental in the digital transformation of Kodak's second-largest business, now Carestream Health Inc. He also acted as an independent director for BioClinica from 2005-2011.
Dr. Brown is the current CEO of Princeton Healthcare Advisory LLC. Dr. Brown served for a decade as a member of the Executive Committee at Covance until 2015, where his responsibilities included M&A as well as licensing and strategic partnership deals. Before joining MedAvante's Board, Brown served the company as a senior adviser, providing counsel on its continuing improvements of electronic clinical outcome assessment (eCOA) administration in CNS studies. His contributions have helped improve the digital data capture functionality of the Virgil Investigative Study Platform.
MedAvante is the global clinical data services company dedicated to maximizing signal detection in clinical trials. Founded in 2002, MedAvante pioneered Central Ratings, a groundbreaking clinical trial methodology. This heritage of clinical expertise, coupled with technical innovation and operational skills, enabled MedAvante to develop the electronic source (eSource) platform, Virgil, the first such technology to replace costly and error-prone paper rating scales with real-time digital collection and cloud management of source data. Designed by clinicians for clinicians, Virgil offers built-in clinical guidance to ensure accurate, standardized assessments. MedAvante helps brings better drug therapies to market through smarter, faster clinical trials. Based in Hamilton, NJ with operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit www.medavante.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/two-former-covance-senior-executives-join-medavante-board-of-directors-300288004.html
SOURCE MedAvante, Inc.